NL-OMON36129已完成不适用
A phase I, single center, randomized, double blind, placebo controlled, single ascending dose study to investigate the safety, tolerability, and pharmacokinetics of GRC 17536, a new TRPA1 antagonist, in healthy volunteers. - Safety, Tolerability, Pharmacokinetics, Food Effect of GRC 17536
Glenmark Pharmaceuticals SA0 个研究点目标入组 76 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 76
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •18 - 45 years of age, male, BMI 18.0 - 28.0 kg/m2, no smokers.
排除标准
- •Suffering from: hepatitis B, cancer or HIV/AIDS. In case of participation in another drug study within 60 days before the start of this study or being a blood donor within 90 days from the start of the study. In case of donating more than 1.5 liters of blood in the 10 months prior the start of this study.
研究者
相似试验
已完成
不适用
A phase 1, single center, randomized, double-blind, placebo-controlled, single (Part 1) and multiple (Part 2) ascending dose study to evaluate the safety,tolerability, pharmacokinetics and pharmacodynamics of M281 administered to healthy volunteers.auto-immuunziekten en ontstekingsziekten.autoimmune diseases and inflammatory diseasesNL-OMON43123Momenta Pharmaceuticals, Inc.74
已完成
1 期
A Phase I, randomised, double blind, placebo-controlled, single ascending dose study to evaluate the safety and tolerability of allogeneic adipose-derived mesenchymal stem cells injected into patients with osteoarthritis of the knee.Musculoskeletal - OsteoarthritisOsteoarthritisACTRN12617001095358Magellan Biologicals Pty Ltd40
尚未招募
不适用
A single-center, double-blind, randomized, phase I/II dose escalating study to assess the safety, tolerability and immunogenicity of three doses of the therapeutic synthetic long peptide (SLP) vaccine (ISA104) in patients with chronic hepatitis B (cHBV).chronic hepatitis BcHBV10047438NL-OMON51362Erasmus MC, Universitair Medisch Centrum Rotterdam24
已完成
不适用
A Phase I, single*center, double-blind, randomized, placebo-controlled, single and multiple ascending dose trial to evaluate the safety and pharmacokinetics of PTC857 in healthy volunteers.10007951Parkinson's DiseaseNL-OMON49571PTC Therapeutics, Inc.82
尚未招募
1 期
A Phase 1, Single Centre, Randomized, Double Blind, Placebo Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of NeuroDirect Ketamine in Healthy Adult VolunteersMental Health - Other mental health disordersPost-traumatic stress disorderACTRN12623000061639Psycheceutical, Inc24